Hormone Receptor-Positive Subtypes

Hormone receptor-positive (HR+) breast cancers represent the most prevalent subtype, accounting for approximately 70% of all breast cancer diagnoses. These tumors express estrogen receptors (ER), progesterone receptors (PR), or both, and are typically characterized by slower growth and a more favorable prognosis compared to other subtypes. However, despite the initial responsiveness to endocrine therapies, recurrence and treatment resistance remain significant challenges. These insights form the basis for tailoring treatment approaches and predicting outcomes.The main focus will be on endocrine therapy, which remains the cornerstone of treatment for HR+ breast cancer. Speakers will examine the use of selective estrogen receptor modulators (SERMs) such as tamoxifen, aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs), highlighting indications, efficacy, and adverse effect profiles. Recent updates to guidelines regarding extended adjuvant endocrine therapy duration, especially in high-risk patients, will be presented along with patient selection criteria. 

    Related Conference of Hormone Receptor-Positive Subtypes

    October 13-14, 2025

    8th International Conference on Anti-Cancer Drugs & Therapies

    Paris, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    4th Experts Meeting on Cancer Medicine, Radiology & Treatment

    Paris, France
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 20-21, 2025

    38th Conference on Preventive Oncology and Diagnostic Cancer

    Rome, Italy
    November 20-21, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    November 24-25, 2025

    16th International Conference on Cancer Stem Cell & Oncology Research

    Barcelona, Spain
    November 24-25, 2025

    47th Euro-Global Summit on Cancer Therapy & Radiation Oncology

    Paris, France
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    December 08-09, 2025

    13th Euro Breast Cancer and Therapeutics

    Aix-en-Provence, France
    February 05-06, 2026

    11th World Conference on Breast and Cervical Cancer

    Paris, France
    February 12-13, 2026

    4th World Congress on Oral Cancer

    Singapore City, Singapore
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France
    April 13-14, 2026

    23rd International Conference on Breast Pathology and Cancer Diagnosis

    Tokyo, Japan
    May 11-12, 2026

    4th International Conference on Cancer Biology and Therapeutics

    Rome, Italy
    June 18-19, 2026

    10th Global Meeting on Oncology and Radiology

    Paris, France
    June 22-23, 2026

    16th World Congress on Breast Cancer

    Dubai, UAE
    June 22-23, 2026

    46th Euro Congress on Cancer Science & Therapy

    Dubai, UAE
    July 27-28, 2026

    6th World Congress on Breast Cancer

    Rome, Italy

    Hormone Receptor-Positive Subtypes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in